Login
Site Search
Trauma-List Subscription
Modify Your Subscription
Home >
List Archives
The Command System for Intensive Care Units in disaster situations
Mehmet ERYILMAZ mehmeteryilmaz at hotmail.comTue Sep 9 10:28:24 BST 2008
- Previous message: peds consults
- Next message: Ideal Trauma and Clinical Kit at Sea
- Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]
Hi all, I am looking for plans (or suggests /thoughts) in which patients at ICUs were evacuated in the disaster situations. Do you have any experience or literature ? Any response either positive or negative would be apreciated. Mehmet ERYILMAZ Col. Turkish Army General Surgeon, Ass Prof. Dept. Emergency Medicine and Surgery Gulhane Military Medical Academy Etlik 06018 Ankara TURKEY mehmeteryilmaz at hotmail.com drmehmeteryilmaz at gmail.com www.mehmeteryilmaz.com Mobile: +90 533 291 3601 Coordinator: Medical Intervention Course for Combat Medic, Turkish Armed Forces Coordinator: Triage Simulation and Moulage Kit Application Course for Military Medical Person, Turkish Armed Forces Editor. Textbook of Disaster Medicine (Incl. 150 contribitors. 2nd Published) Editor. Turkish Journal of Disaster Medicine Deputy Commander. DAKIK Military Mobile Surgical Hospital, Turkish Armed Forces Scientific Secretary of The National Congress of Disaster Medicine, 2004 To: From: Jeff.Rubin at tvfr.com Subject: NATO MCI FW: Biosecurity Briefing: proposed OSHA guidance Date: Wed, 21 May 2008 18:30:54 -0700 Please note the item in the Center for Biosecurity's excellent newsletter on OSHA's proposed guidance on workplace stockpiling of certain PPE for pan-flu The proposed guidelines may be viewed online at http://www.osha gov/dsg/guidance/stockpiling-facemasks-respirators.html, or downloaded in PDF at http://www.osha gov/dsg/guidance/proposedGuidanceStockpilingRespirator.pdf. The website for comments is at http://www.osha.gov/pls/oshaweb/owadisp show_document?p_table=FEDERAL_REGISTER&p_id=20383, but if you really want to submit them it's a convoluted path, so you can skip the search and go straight to http://www.regulations gov/fdmspublic/component/main?main=SubmitComment&o=0900006480556ffa: comments due by 7/9/08. Comments or not, it worth a look. If you have not seen the Initial guidelines to which this serves as an appendix, it's at http://www.osha.gov/Publications/influenza_pandemic.html. These documents are also linked on our workplace pandemic preparedness site, http://www.tvfr com/dept/em/em_business.html#panflu. JNR Jeff Rubin, PhD, CEM® Emergency Manager Tualatin Valley Fire & Rescue (503) 642-0399 (O - direct) (503) 970-3611 (cell/pager) (503) 642-4814 (fax) jeff.rubin at tvfr.com http://www.tvfr.com Hospital Preparedness website: http://www.tvfr.com/dept/em/em_hospitals.html "Man invented language to satisfy his deep need to complain." (Lily Tomlin) From: Center for Biosecurity of UPMC [mailto:bb_editor at upmc-biosecurity.org] Sent: Friday, May 16, 2008 12:10 PM To: Rubin, Jeffrey N. Subject: Biosecurity Briefing Biosecurity Briefing Please add bbeditor at upmc-biosecurity.org to your email contacts. May 16, 2008 FDA Approves Antimicrobial for Pediatric Inhalational Anthrax Exposure OSHA Seeks Public Comment on Workplace Stockpiling Guidance Indonesia to Share H5N1 Data with New GISAID Database FDA Approves Antimicrobial for Pediatric Inhalational Anthrax Exposure According to a Drug Industry Daily news report, the U.S. Food and Drug Administration (FDA) approved Levaquin® (levofloxacin) for use in pediatric patients who have been exposed to Bacillus anthracis.1 This is the first and only pediatric indication for Levaquin. Levaquin, which is a quinolone antimicrobial agent manufactured by Ortho-McNeil, is approved for this indication in children six months of age or older in 250 mg, 500 mg, and 750 mg strength tablets, 5 mg/mL injection, and 25 mg/mL oral solution.1,2 While it has not been tested in humans for the post-exposure prevention of inhalational anthrax, Levaquin was already approved by the FDA to treat adults to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.2 Brooke Courtney References Astor A. Levaquin approved for pediatric anthrax exposure. Drug Industry Daily. May 8, 2008. http://www.fdanews com/newsletter/article?articleId=106558&issueId=11568. Accessed May 15, 2008 Levaquin: Highlights of Prescribing Information. February 2008. http://www levaquin.com/levaquin/shared/pi/levaquin.pdf#zoom=100. Accessed May 15, 2008 OSHA Seeks Public Comment on Workplace Stockpiling Guidance On May 9, 2008, the Occupational Safety and Health Administration (OSHA) of the U.S. Department of Labor released proposed guidance on workplace stockpiling of facemasks and respirators for pandemic influenza and is seeking public comment. OSHA recommends workplace stockpiling because manufacturing capacity at the time of an outbreak would not meet the expected demand and employers will be able to better protect their employees as well as lessen the impact of a pandemic on their business, society, and the economy.1 The guidance recommends that employers categorize employee positions into four risk types, according to the likelihood of employees occupational exposure to pandemic influenza.1 The categories are: Very High Exposure Risk: Healthcare or laboratory employees who perform tests on pandemic patients or work with patient samples in a laboratory High Exposure Risk: Healthcare employees who work in patient rooms, transport patients, or perform autopsies on pandemic patients Medium Exposure Risk: Employees who interact frequently with and have exposure to the general population Low Exposure Risk: Employees with limited contact with patients or the general public At each risk level, the guidance provides formulas for determining the number and type of respirators or facemasks needed and for calculating the total approximate cost of respirators and facemasks associated with a 120 day pandemic period. There is also a description of the types of respirators to use during a pandemic, including disposable, surgical, reusable elastomeric, and powered air purifying respirators. Additionally, the document provides benefits, drawbacks and price ranges for each type of respirator. According to OSHA, although inexpensive, surgical facemasks provide only a physical barrier against large droplets of blood or body fluids.1 In contrast, respirators reduce an employees exposure to airborne contaminants; however, they can cost between $0.50 and $1200 per unit, depending on the sophistication of the device.1 The OSHA guidance is being offered as an appendix to Guidance on Preparing Workplaces for an Influenza Pandemic (jointly issued by the Department of Labor and the Department of Health and Human Services) which was released in February 2007. The new guidance document will be open for public comment until July 8, 2008, and instructions for submitting comments can be found at: http://www.osha.gov/pls/oshaweb/owadisp show_document?p_table=FEDERAL_REGISTER&p_id=20383 Kunal Rambhia Reference Occupational Health and Safety Administration. U.S. Department of Labor. Proposed guidance on workplace stockpiling of respirators and facemasks for pandemic influenza. May 9, 2008. http://www.osha gov/dsg/guidance/stockpiling-facemasks-respirators.html. Accessed May 16, 2008. Indonesia to Share H5N1 Data with New GISAID Database On May 16, 2008, health officials from Indonesia announced that the republic would begin sharing information about H5N1 cases with a new global database known as the Global Initiative on Sharing Avian Influenza Data (GISAID). According to an Associated Press (AP) report, GISAID is a free online database that launched on May 15, 2008; it is not affiliated with the World Health Organizations flu database.1 The new database calls on users to reach an agreement with data providers before applying, for example, for patents needed for vaccines. In addition, GISAID has created an electronic tracking system that enables site users to see who has sent or received virus datafrom government laboratories to pharmaceutical companies in order to preserve transparency.1 The AP article notes that GISAID was developed after a group of more than 70 preeminent scientists published a letter in the journal Nature that calling for avian influenza information be shared more quickly and openly.1 Specifically, the scientists rejected the traditional practice in which individual organizations maintained private databases of viral genetic information. According to the article, the WHOs H5N1 flu information was held in a database based out of Los Alamos, New Mexico, which was accessible to only 15 laboratories. In 2007, the WHO acknowledged an urgent need to address the international skepticism about process for sharing flu data. However, the AP article notes that the WHO does still believe that some genetic data should be kept behind closed doors. To that end, the WHO is seeking $10 million to implement another database and tracking system.1 The AP article notes that scientists, including members of WHOs four influenza collaborating centers, have expressed skepticism regarding the WHOs plans to develop a new database now that GISAID has been launched. These scientists have said that GISAID has been tailor-made by and for influenza scientists and they argue that full transparency will not hinder efforts to carry out their vaccine strain selection process.1 Jennifer Nuzzo Reference McDowell R. Indonesia hands over bird flu data to new database. Associated Press. May 16, 2008. http://ap.google com/article/ALeqM5ilPWosUPwePm-tfuKZJ_-YVEd81QD90M8FAG0. Accessed May 18, 2008. About the Briefing | Privacy Policy | Terms of Use | Center for Biosecurity of UPMC Email the editor: bb_editor at upmc-biosecurity.org Click here to Unsubscribe Copyright © 2007 University of Pittsburgh Medical Center. All rights reserved. This letter send to you by the NATO MCI protocol list See how Windows Mobile brings your life togetherat home, work, or on the go See Now This letter send to you by the NATO MCI protocol list --^^--------------------------------------------------------------- This email was sent to: mehmeteryilmaz at hotmail.com EASY UNSUBSCRIBE click here: http://topica.com/u/?b1dr0f.bOYJmM.bWVobWV0 Or send an email to: natomci-unsubscribe at topica.com For Topica's complete suite of email marketing solutions visit: http://www.topica.com/?p=TEXFOOTER --^^--------------------------------------------------------------- -------------- next part -------------- A non-text attachment was scrubbed... Name: not available Type: image/gif Size: 31851 bytes Desc: not available URL: <http://list.mistral.net/pipermail/trauma-list/attachments/20080909/acf7eb1c/attachment.gif>
- Previous message: peds consults
- Next message: Ideal Trauma and Clinical Kit at Sea
- Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]
More information about the trauma-list mailing list
